Boston Scientific Corp

BSX-N

NYSE:BSX

37.42
0.49 (1.29%)
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional ...
More at Wikipedia

Analysis and Opinions about BSX-N

Signal
Opinion
Expert
COMMENT
COMMENT
March 5, 2020
Had an exceptional 10 years. Sold off heavily with the coronavirus. High growth. Challenge is you couldn't buy it if you were a value investor. Supply of components will be an issue, as for all its peers.
Show full opinionHide full opinion
Had an exceptional 10 years. Sold off heavily with the coronavirus. High growth. Challenge is you couldn't buy it if you were a value investor. Supply of components will be an issue, as for all its peers.
TOP PICK
TOP PICK
February 24, 2020
They make global medical devices. A steady eddy pick and a good way to play healthcare. Their Q4 report sucked, so the stock sold off, but this has outperformed the medical devices and healthcare indexes before Q4. Q4 was a hiccup, so it's now a buying opportunity or around $40. (Analysts’ price target is $49.14)
Show full opinionHide full opinion
They make global medical devices. A steady eddy pick and a good way to play healthcare. Their Q4 report sucked, so the stock sold off, but this has outperformed the medical devices and healthcare indexes before Q4. Q4 was a hiccup, so it's now a buying opportunity or around $40. (Analysts’ price target is $49.14)
BUY WEAKNESS
BUY WEAKNESS
January 10, 2020
Changing demographics? He has a model price of $45.83 per share -- right around current prices. A move higher in the market could take it to $61. He would wait thru the next earnings announcement. It is not cheap here. He would wait for a pullback before buying in.
Show full opinionHide full opinion
Changing demographics? He has a model price of $45.83 per share -- right around current prices. A move higher in the market could take it to $61. He would wait thru the next earnings announcement. It is not cheap here. He would wait for a pullback before buying in.
PAST TOP PICK
PAST TOP PICK
September 16, 2019

(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.

Show full opinionHide full opinion

(A Top Pick Sep 18/18, Up 11%) They make heart pacers and have expanded into joint replacements through acquisitions. It was poorly managed, but has turned around in the past three years. He's trimmed around $42 to be Pfizer. However, all medical stocks face US politicians bashing them during elections. So, load up on health stocks and do well after the vote.

BUY
BUY
July 17, 2019
Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.
Show full opinionHide full opinion
Since 2014, management has executed very good 7-9% organic EPS growth while compressing margins on the cost side. Last quarter, though, they had a hiccup with their Watchman device, but the market forgave them because of BSX's track record. Happy to own it. They report next week. If they miss, expect volatility.
BUY
BUY
July 8, 2019
They've done a good job turning around in the past 7 years with a new CEO. Margins will continue to rise with high single-digit growth. Legal settlements and tax issues are behind them, thus freeing up their cash. This is a big holding for him.
Show full opinionHide full opinion
They've done a good job turning around in the past 7 years with a new CEO. Margins will continue to rise with high single-digit growth. Legal settlements and tax issues are behind them, thus freeing up their cash. This is a big holding for him.
HOLD
HOLD
May 3, 2019
Likes 2-year time horizon. A stellar performer. Executing on top and bottom line. An example of how margins should be. Couple of new products are coming out, and one of best organic growth profiles in the sector. This quarter was the first hiccup in a long time, but the market gave them a pass. He'll give them another quarter to prove themselves.
Show full opinionHide full opinion
Likes 2-year time horizon. A stellar performer. Executing on top and bottom line. An example of how margins should be. Couple of new products are coming out, and one of best organic growth profiles in the sector. This quarter was the first hiccup in a long time, but the market gave them a pass. He'll give them another quarter to prove themselves.
BUY
BUY
April 8, 2019
BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it.
Show full opinionHide full opinion
BSX-N vs. TFX-N. TFX-N is a smaller high growth company. BSX-N is a market leader but recovering from a few years of bad management. He has a low $40s target in a year. He would stick with it.
BUY
BUY
January 7, 2019
He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions.
Show full opinionHide full opinion
He still loves this name. You can still buy it in the low $30s and he has a target of the low $40s. They are making acquisitions.
BUY
BUY
September 18, 2018

He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model.

Show full opinionHide full opinion

He sold shares in Medtronics (MDT-N) to buy this, which he sees as more of a turnaround play. He sees higher growth prospects in their more targeted business model.

TOP PICK
TOP PICK
September 18, 2018

The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78)

Show full opinionHide full opinion

The company has raised its growth rate from 5-to-7% to 7-to-10% range. This is a strong turnaround, and he is excited about medical stocks doing better. Yield 0%. (Analysts’ price target is $38.78)

BUY
BUY
July 5, 2018

He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates.

Show full opinionHide full opinion

He likes it. They are in cardiac arrhythmia management and cardiology devices. Best in class organic growth. They made 8 acquisitions over the past year or so. Might be a target for an acquisition. One of his favorites option candidates.

BUY
BUY
April 2, 2018

On the 5 year chart you can see it is in an uptrend. It is quite tradable. It began to find a lid just under $30. Buy in the low $20s and sell in the high $20’s. Don’t own it for the long run.

Show full opinionHide full opinion

On the 5 year chart you can see it is in an uptrend. It is quite tradable. It began to find a lid just under $30. Buy in the low $20s and sell in the high $20’s. Don’t own it for the long run.

HOLD
HOLD
March 21, 2018

No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold.

Show full opinionHide full opinion

No dividend, focussed on cardiac equipment like pacemakers. Have made many acqusitions in past years. Fabulous management. Have driven cost synergies consistently. Beat estimates recently. Forward earnings are 20x. A solid hold.

COMMENT
COMMENT
October 26, 2017

If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here.

Show full opinionHide full opinion

If you own healthcare providers, especially in the hospital supply area, they have been great stocks for a long time. We are all getting older and need more help. Prefers Medtronic (MDT-N) a little better. However, this is another dividend growth story, so you can’t go wrong here.

Showing 1 to 15 of 30 entries

Boston Scientific Corp(BSX-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 4

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 4

Stockchase rating for Boston Scientific Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Boston Scientific Corp(BSX-N) Frequently Asked Questions

What is Boston Scientific Corp stock symbol?

Boston Scientific Corp is a American stock, trading under the symbol BSX-N on the New York Stock Exchange (BSX). It is usually referred to as NYSE:BSX or BSX-N

Is Boston Scientific Corp a buy or a sell?

In the last year, 4 stock analysts published opinions about BSX-N. 4 analysts recommended to BUY the stock. 0 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Boston Scientific Corp.

Is Boston Scientific Corp a good investment or a top pick?

Boston Scientific Corp was recommended as a Top Pick by Darren Sissons on 2020-03-05. Read the latest stock experts ratings for Boston Scientific Corp.

Why is Boston Scientific Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Boston Scientific Corp worth watching?

4 stock analysts on Stockchase covered Boston Scientific Corp In the last year. It is a trending stock that is worth watching.

What is Boston Scientific Corp stock price?

On 2020-06-04, Boston Scientific Corp (BSX-N) stock closed at a price of $37.42.